<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917110</url>
  </required_header>
  <id_info>
    <org_study_id>P2013/05</org_study_id>
    <nct_id>NCT01917110</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.</brief_title>
  <official_title>Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coopervision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coopervision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon&#xD;
      A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset&#xD;
      myopia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects in two parallel groups were randomized and assigned to either the study contact lens&#xD;
      (omafilcon a) or single vision spectacles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2013</start_date>
  <completion_date type="Actual">June 16, 2016</completion_date>
  <primary_completion_date type="Actual">June 16, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the spherical equivalent refractive error relative to baseline.</measure>
    <time_frame>Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in axial length relative to baseline.</measure>
    <time_frame>Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of corneal curvature (keratometry)relative to baseline.</measure>
    <time_frame>Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of pupil diameter relative to baseline.</measure>
    <time_frame>Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>omafilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contact Lens Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectacle Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prescription at Baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>omafilcon A</intervention_name>
    <arm_group_label>omafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectacle</intervention_name>
    <arm_group_label>Spectacle Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior to being considered eligible to participate in this study, each subject MUST:&#xD;
&#xD;
               1. Be between 8 and 12 years of age inclusive at the baseline examination.&#xD;
&#xD;
               2. Have:&#xD;
&#xD;
                    1. read the Informed Assent,&#xD;
&#xD;
                    2. been given an explanation of the Informed Assent,&#xD;
&#xD;
                    3. indicated an understanding of the Informed Assent and&#xD;
&#xD;
                    4. signed the Informed Assent Form.&#xD;
&#xD;
               3. Have their parent or legal guardian:&#xD;
&#xD;
                    1. read the Informed Consent,&#xD;
&#xD;
                    2. been given an explanation of the Informed Consent,&#xD;
&#xD;
                    3. indicated an understanding of the Informed Consent and&#xD;
&#xD;
                    4. signed the Informed Consent Form.&#xD;
&#xD;
               4. Along with their parent or guardian, be capable of comprehending the nature of&#xD;
                  the study, and be willing and able to adhere to the instructions set forth in&#xD;
                  this protocol.&#xD;
&#xD;
               5. Along with their parent or guardian, agree to maintain the visit schedule and be&#xD;
                  able to keep all appointments as specified in the study protocol for the duration&#xD;
                  of the study&#xD;
&#xD;
               6. Agree to accept either the control or test lens as assigned by the randomisation&#xD;
                  scheme.&#xD;
&#xD;
               7. Agree to wear the assigned contact lenses for the duration of the 2 year study&#xD;
                  and to inform the study investigator if this schedule is interrupted. (Wearing&#xD;
                  time may be modified by the study staff for health reasons.)&#xD;
&#xD;
               8. Possess wearable and visually functional eyeglasses.&#xD;
&#xD;
               9. Be in good general health, based on his/her and parent's/guardian's knowledge.&#xD;
&#xD;
              10. Have best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25&#xD;
                  Snellen equivalent) or better in each eye.&#xD;
&#xD;
              11. Meet the following refractive criteria determined by cycloplegic autorefraction&#xD;
                  at baseline:&#xD;
&#xD;
                    1. Spherical Equivalent Refractive Error (SERE): between -0.75 and -4.00 D&#xD;
                       inclusive.&#xD;
&#xD;
                    2. Astigmatism: &lt; -0.75 D&#xD;
&#xD;
                    3. Anisometropia: &lt; 1.00D&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects may not be considered eligible if ANY of the following apply:&#xD;
&#xD;
               1. Subject has previously or recently worn soft or rigid gas permeable contact&#xD;
                  lenses, including orthokeratology lenses.&#xD;
&#xD;
               2. Subject appears to exhibit poor personal hygiene (that in the investigator's&#xD;
                  opinion might prevent safe contact lens wear).&#xD;
&#xD;
               3. Subject is currently or prior to this study has been an active participant in&#xD;
                  another clinical study.&#xD;
&#xD;
               4. Parent / guardian or close relative is a member, of the office staff, including&#xD;
                  the investigator(s).&#xD;
&#xD;
               5. Current or prior use of bifocals, progressive addition lenses, atropine,&#xD;
                  pirenzepine or ANY other myopia control treatment.&#xD;
&#xD;
               6. Subject was born earlier than 30 weeks or weighed less than 1500g (3.3lb) at&#xD;
                  birth.&#xD;
&#xD;
               7. Regular use of ocular medications (prescription or over-the-counter), artificial&#xD;
                  tears, or wetting agents.&#xD;
&#xD;
               8. Current use of systemic medications which may significantly affect contact lens&#xD;
                  wear, tear film production, pupil size, accommodation or refractive state. Such&#xD;
                  as, but not limited to: long term use of nasal decongestants (for example,&#xD;
                  pseudoephedrine, phenylephrine), antihistamines (for example, chlorpheniramine,&#xD;
                  diphenhydramine), Prednisolone or Ritalin (methylphenidate).&#xD;
&#xD;
               9. A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.&#xD;
&#xD;
              10. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer,&#xD;
                  corneal infiltrates, ocular viral or fungal infections or other recurrent ocular&#xD;
                  infections.&#xD;
&#xD;
              11. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance&#xD;
                  correction.&#xD;
&#xD;
              12. Known ocular or systemic disease such as, but not limited to: anterior uveitis or&#xD;
                  iritis, episcleritis or scleritis, glaucoma, Sjogren's syndrome, lupus&#xD;
                  erythematosus, scleroderma, or diabetes.&#xD;
&#xD;
              13. Any ocular, systemic or neuro-developmental conditions that could influence&#xD;
                  refractive development. Such as, but not limited to: persistent pupillary&#xD;
                  membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis eyelid&#xD;
                  hemangiomas, Marfan's Syndrome, Down's syndrome, Ehler's-Danlos syndrome,&#xD;
                  Stickler's syndrome, ocular albinism, retinopathy of prematurity.&#xD;
&#xD;
              14. Keratoconus or an irregular cornea.&#xD;
&#xD;
              15. Biomicroscope findings that would contraindicate contact lens wear including, but&#xD;
                  not limited to:&#xD;
&#xD;
                    1. corneal scars within the visual axis&#xD;
&#xD;
                    2. neovascularisation or ghost vessels &gt; 1.5 mm in from the limbus&#xD;
&#xD;
                    3. Any active anterior segment ocular disease that would contraindicate contact&#xD;
                       lens wear.&#xD;
&#xD;
                    4. giant papillary conjunctivitis of Grade 2 or worse&#xD;
&#xD;
                    5. allergic or seasonal conjunctivitis (if the study investigator believes it&#xD;
                       could significantly interfere with maintaining the specified contact lens&#xD;
                       wearing schedule)&#xD;
&#xD;
                    6. clinically significant (Grade 3 or 4) abnormalities of the anterior segment,&#xD;
                       lids, conjunctiva, sclera or associated structures.&#xD;
&#xD;
              16. The investigator for any reason considers that it is not in the best interest of&#xD;
                  the subject to participate in the study.&#xD;
&#xD;
              17. Have pathological myopia To be eligible to begin the study, a subject must have&#xD;
                  ALL of the inclusion criteria and NONE of the exclusion criteria present.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesar Villa Collar, OD PhD FAAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Optica y Optometria de la Universidad Europea de Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departamento de Óptica y Optometría de la Universidad Europea de Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

